Valuation dashboard for Protalix BioTherapeutics, Inc. (PLX) with P/E 11.12, P/B 3.00, EV/EBITDA 7.49 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Analysis Summary
Protalix BioTherapeutics, Inc. reported revenue of $52.7M in the most recent fiscal year, growing at a 5-year CAGR of -3.5%.
Trailing-twelve-month margins: gross margin 69.2%, operating margin 28.9%, net margin 23.5%.
At the current price of $2.68, PLX trades at a P/E of 11.12 and an ROE of 31.61%. Market capitalisation stands at $216M.
Balance sheet quality for PLX: current ratio of 2.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 11.12 |
| Price / Book | 3.00 |
| EV / EBITDA | 7.49 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | $216M | 11.12 | 3.00 | 31.6% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.68 |
| Market Cap | $216M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | 31.61% |
| Return on Invested Capital | 23.33% |
| Return on Assets | 17.17% |
| Gross Margin | 69.20% |
| Operating Margin | 28.89% |
| Net Margin | 23.50% |
Related companies: CDXS · CHRS · GNFT · IVVD · MDWD · NTHI · OABI
Explore sector: Healthcare · Biotechnology
More sections of PLX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks